Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape
Cibus (Nasdaq: CBUS) has completed initial field tests of its Pod Shatter Reduction (PSR) trait in winter oilseed rape in the UK, marking the first gene-edited trait to complete such trials in the country. The promising results support Cibus' ongoing commercial development of the PSR trait. This milestone was made possible by simplified UK regulations introduced in 2022, allowing for science-based testing of gene-edited traits.
Cibus utilizes its proprietary Rapid Trait Development System™ (RTDS®) to develop complex gene-edited traits. The PSR trait aims to address potential yield losses of 5% to 25% due to pod shatter in winter oilseed rape. The successful trials pave the way for a second season of testing, with Cibus looking to deliver the benefits of precision breeding to UK farmers and the broader European agricultural community.
Cibus (Nasdaq: CBUS) ha completato i test iniziali sul campo del suo tratto di riduzione della rottura delle capsule (PSR) nella colza invernale nel Regno Unito, segnando il primo tratto editato geneticamente a completare tali prove nel paese. I risultati promettenti supportano lo sviluppo commerciale in corso del tratto PSR da parte di Cibus. Questo traguardo è stato reso possibile dalle normative semplificate introdotte nel Regno Unito nel 2022, che consentono test scientifici basati su tratti modificati geneticamente.
Cibus utilizza il suo Rapid Trait Development System™ (RTDS®) per sviluppare tratti complessi editati geneticamente. Il tratto PSR mira a affrontare potenziali perdite di resa dal 5% al 25% a causa della rottura delle capsule nella colza invernale. I test di successo aprono la strada a una seconda stagione di prove, con Cibus che mira a fornire i benefici della selezione di precisione agli agricoltori del Regno Unito e alla comunità agricola europea più ampia.
Cibus (Nasdaq: CBUS) ha completado las pruebas iniciales de campo de su característica de reducción de la rotura de vainas (PSR) en colza invernal en el Reino Unido, marcando la primera característica editada genéticamente en completar tales ensayos en el país. Los resultados prometedores respaldan el desarrollo comercial continuo de Cibus para la característica PSR. Este hito fue posible gracias a la simplificación de las regulaciones del Reino Unido introducidas en 2022, que permiten pruebas basadas en la ciencia sobre rasgos editados genéticamente.
Cibus utiliza su Rapid Trait Development System™ (RTDS®) para desarrollar rasgos complejos editados genéticamente. La característica PSR tiene como objetivo abordar pérdidas potenciales de rendimiento del 5% al 25% debido a la rotura de vainas en la colza invernal. Los ensayos exitosos allanan el camino para una segunda temporada de pruebas, con Cibus buscando proporcionar los beneficios de la cría de precisión a los agricultores del Reino Unido y a la comunidad agrícola europea más amplia.
Cibus(Nasdaq: CBUS)는 영국에서 겨울 유채에 대한 콩 꼬투리 파손 감소(PSR) 특성 초기 현장 테스트를 완료했습니다. 이는 해당 국가에서 처음으로 유전자 편집 특성이 이러한 시험을 완료했다는 것을 의미합니다. 유망한 결과는 Cibus의 PSR 특성의 지속적인 상업적 개발을 지원합니다. 이 이정표는 2022년에 도입된 간소화된 영국 규정 덕분에 가능해졌으며, 이는 유전자 편집 특성에 대한 과학 기반 테스트를 허용합니다.
Cibus는 신속한 특성 개발 시스템™ (RTDS®)을 활용하여 복잡한 유전자 편집 특성을 개발합니다. PSR 특성은 겨울 유채에서 꼬투리 파손으로 인한 5%에서 25%의 잠재적 수확 손실을 해결하는 것을 목표로 합니다. 성공적인 시험은 두 번째 시험 시즌을 위한 길을 열으며, Cibus는 영국 농부들과 더 넓은 유럽 농업 공동체에 정밀 육종의 이점을 제공할 계획입니다.
Cibus (Nasdaq: CBUS) a terminé les tests initiaux sur le terrain de son caractéristique de réduction de la rupture des gousses (PSR) dans le colza d'hiver au Royaume-Uni, marquant le premier caractère édité génétiquement à compléter de tels essais dans le pays. Les résultats prometteurs soutiennent le développement commercial continu de Cibus pour le caractère PSR. Cette étape a été rendue possible grâce à des réglementations britanniques simplifiées introduites en 2022, permettant des tests basés sur la science des traits modifiés génétiquement.
Cibus utilise son Système de développement rapide de traits™ (RTDS®) pour développer des traits complexes modifiés génétiquement. Le caractère PSR vise à aborder les pertes potentielles de rendement de 5 % à 25 % dues à la rupture des gousses dans le colza d'hiver. Les essais réussis ouvrent la voie à une deuxième saison d'essais, avec Cibus cherchant à offrir les avantages de la sélection de précision aux agriculteurs britanniques et à la communauté agricole européenne au sens large.
Cibus (Nasdaq: CBUS) hat die ersten Feldversuche seines Merkmals zur Verringerung von Schotenbrüchen (PSR) bei Winterraps im Vereinigten Königreich abgeschlossen, wodurch es sich um das erste genschädiged Merkmal handelt, das solche Versuche im Land abschließt. Die vielversprechenden Ergebnisse unterstützen die laufende kommerzielle Entwicklung des PSR-Merkmals durch Cibus. Dieser Meilenstein wurde durch die 2022 eingeführten vereinfachten Vorschriften im Vereinigten Königreich ermöglicht, die wissenschaftlich fundierte Tests genschädigter Merkmale erlauben.
Cibus nutzt sein Rapid Trait Development System™ (RTDS®), um komplexe genschädigte Merkmale zu entwickeln. Das PSR-Merkmal zielt darauf ab, potenzielle Ertragsverluste von 5% bis 25% aufgrund von Schotenbrüchen bei Winterraps anzugehen. Die erfolgreichen Versuche ebnen den Weg für eine zweite Testphase, dabei möchte Cibus den britischen Landwirten und der breiteren europäischen Landwirtschaftsgemeinschaft die Vorteile der Präzisionszucht bieten.
- Successful completion of initial field trials for Pod Shatter Reduction trait in UK winter oilseed rape
- Promising results support continued commercial development of PSR trait
- Potential to address yield losses of 5% to 25% in winter oilseed rape due to pod shatter
- Second season of trials already underway
- None.
The completion of Cibus' first field trials for Pod Shatter Reduction (PSR) in winter oilseed rape in the UK marks a significant milestone in agricultural biotechnology. This advancement could potentially increase crop yields by 5% to 25%, addressing a major challenge for farmers. The success of these trials demonstrates the efficacy of Cibus' RTDS® technology in developing complex gene-edited traits. It also highlights the positive impact of streamlined regulations in the UK, enabling faster innovation in crop improvement. If commercialized, this trait could enhance food security and farmer profitability, representing a noteworthy advancement in precision breeding for European agriculture.
Cibus' progress with PSR trait in winter oilseed rape could have substantial market implications. The oilseed rape market in Europe is significant and addressing pod shattering could increase market share for Cibus and its seed company partners. This development may also positively impact Cibus' stock (NASDAQ: CBUS), as it demonstrates the company's ability to deliver on its technology promises. The UK's regulatory approach could serve as a model for other European countries, potentially opening up a larger market for Cibus' gene-edited traits. Investors should monitor the second season of trials and any announcements regarding commercialization timelines, as these will be key indicators of future revenue potential.
The UK's simplified rules for gene-edited crop trials, introduced in 2022, represent a pivotal shift in agricultural policy. This science-based approach has enabled faster innovation, as evidenced by Cibus' rapid progress. It sets a precedent for other European nations to potentially follow, which could accelerate the adoption of beneficial crop traits. However, it's important to maintain rigorous safety assessments throughout the development process. The potential yield improvements from PSR could lead to more efficient land use, potentially reducing the environmental footprint of oilseed rape cultivation. This aligns with broader goals of sustainable intensification in agriculture, balancing productivity with environmental stewardship.
Initial data from Pod Shatter Reduction field trials show promising results
The first gene edited trait to complete field trials in oilseed rape in the UK
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has completed initial field tests of its Pod Shatter Reduction (PSR) trait in the United Kingdom. The initial data from these trials support Cibus’ continuing commercial development of its PSR trait in winter oilseed rape. These trials represent an important progression in the Company’s commercial development with the application of Cibus’ spring oilseed rape (canola) PSR trait to winter oilseed rape.
Simplified rules, introduced in 2022 by the UK Department for the Environment, Food and Rural Affairs led to a science-based and streamlined regulatory approach that enabled Cibus’ PSR trait to be tested in winter oilseed rape under European growing conditions for the first time.
Cibus is a leader in the development of complex gene edited traits in plants like Pod Shatter Reduction in winter oilseed rape. The Company uses its proprietary Rapid Trait Development System™ (RTDS®), which includes techniques such as Gene Repair Oligonucleotides (GRON) and molecular scissors including Transcription activator-like effector nucleases (TALENs), to develop these traits.
Dr. Jim Radtke, Senior Vice President of Product Development at Cibus commented, “The results of these first PSR field trials in winter oilseed rape are very encouraging. We’ve been able to validate our existing PSR trait’s performance under controlled environments now in UK field conditions. These results pave the way for a second season of trials that are now underway.”
Tony Moran, Senior Vice President of International Development and Government Affairs at Cibus added, “Pod shatter in winter oilseed rape can impact growers’ productivity and national food security. With potential yield losses of
About Cibus
Cibus is a leading independent plant trait company that develops and licenses plant traits to seed companies for royalties. Cibus is not a seed company, but rather a technology company that uses its proprietary gene editing technology to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Cibus’ strategy is focused on commercializing productivity traits for the world’s major row crops with large acreage such as: canola, rice, soybean, corn and wheat. The Company targets traits that help manage farmers’ seed productivity and sustainability challenges such as weeds, disease, and insects. The United Nations estimates that the impacts from these challenges cost the global economy approximately
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "anticipates," "believes," "continue," "estimates," "expects," "intends," "may," "might," "plans," "predicts," "projects," "should," "targets," "will," or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the offering and the expected use of the proceeds from the offering. Completion of the offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements made by Cibus’ management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
CIBUS CONTACTS:
INVESTOR RELATIONS
Karen Troeber
ktroeber@cibus.com
858-450-2636
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
media@cibus.com
(619) 849-6009
Colin Sanford
colin@bioscribe.com
203-918-4347
FAQ
What is the significance of Cibus' Pod Shatter Reduction trait field trials in the UK?
How could Cibus' PSR trait impact winter oilseed rape yields?
What technology does Cibus (CBUS) use to develop its gene-edited traits?
When did the UK introduce simplified regulations for gene-edited crop trials?
